See you at #WMS2026 in Hiroshima, Japan 🇯🇵 (29 Sep–3 Oct).
Sylwia Szwec-Jóźwiak will represent Cure MFM13 at the 31st World Muscle Society Congress and share insight into our work on HSPB8-associated myopathy (MFM13).
Coming to Hiroshima? Come say hello 👋
Sylwia Szwec-Jóźwiak will represent Cure MFM13 at the 31st World Muscle Society Congress and share insight into our work on HSPB8-associated myopathy (MFM13).
Coming to Hiroshima? Come say hello 👋
September 28, 2026 at 5:02 PM
See you at #WMS2026 in Hiroshima, Japan 🇯🇵 (29 Sep–3 Oct).
Sylwia Szwec-Jóźwiak will represent Cure MFM13 at the 31st World Muscle Society Congress and share insight into our work on HSPB8-associated myopathy (MFM13).
Coming to Hiroshima? Come say hello 👋
Sylwia Szwec-Jóźwiak will represent Cure MFM13 at the 31st World Muscle Society Congress and share insight into our work on HSPB8-associated myopathy (MFM13).
Coming to Hiroshima? Come say hello 👋
Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy. #NeuroDegeneration 🧪🧠
https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
August 10, 2026 at 4:02 AM
Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy. #NeuroDegeneration 🧪🧠
https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy. https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
August 10, 2026 at 2:43 AM
Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy. https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy. https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
August 10, 2026 at 2:43 AM
Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy. https://www.biorxiv.org/content/10.64898/2026.08.04.742148v1
Did you know the protein behind MFM13 goes by many names?
HSPB8 is a member of the small heat shock protein (sHSP) family and is also known as HSP22, H11 kinase, or protein kinase H11
HSPB8 is a member of the small heat shock protein (sHSP) family and is also known as HSP22, H11 kinase, or protein kinase H11
July 24, 2026 at 5:02 PM
Did you know the protein behind MFM13 goes by many names?
HSPB8 is a member of the small heat shock protein (sHSP) family and is also known as HSP22, H11 kinase, or protein kinase H11
HSPB8 is a member of the small heat shock protein (sHSP) family and is also known as HSP22, H11 kinase, or protein kinase H11
First natural history study on msps that includes hspb8-related diseases is now underway – and you can contribute!
📢 New academic initiative aimed at characterizing multisystem proteinopathies
We invite colleagues worldwide who have diagnosed patients with genetic variants in MSP-associated genes to participate in this international collaboration
Find out more: bit.ly/4qjIRkH
We invite colleagues worldwide who have diagnosed patients with genetic variants in MSP-associated genes to participate in this international collaboration
Find out more: bit.ly/4qjIRkH
July 9, 2026 at 2:36 PM
First natural history study on msps that includes hspb8-related diseases is now underway – and you can contribute!
🎙️ New Journal Club episode!
We review Putko et al. (2026), who describe two patients with HSPB8 variants and overlapping features of myopathy and distal motor neuropathy. The study expands the clinical and pathological spectrum of HSPB8-associated disease.
🎧 Listen:
We review Putko et al. (2026), who describe two patients with HSPB8 variants and overlapping features of myopathy and distal motor neuropathy. The study expands the clinical and pathological spectrum of HSPB8-associated disease.
🎧 Listen:
Free Podcast Hosting – Unlimited Episodes & Audio | RSS.com
Start your podcast free with RSS.com! Unlimited episodes, RSS feed, analytics, and tools to grow and monetize your show.
buff.ly
June 18, 2026 at 5:04 PM
🎙️ New Journal Club episode!
We review Putko et al. (2026), who describe two patients with HSPB8 variants and overlapping features of myopathy and distal motor neuropathy. The study expands the clinical and pathological spectrum of HSPB8-associated disease.
🎧 Listen:
We review Putko et al. (2026), who describe two patients with HSPB8 variants and overlapping features of myopathy and distal motor neuropathy. The study expands the clinical and pathological spectrum of HSPB8-associated disease.
🎧 Listen:
Lei et al. recently published a study exploring how non-coding RNAs regulate HSPB8 expression and influence neuroprotection after cerebral infarction (stroke).
Check out full article
Check out full article
The Molecular Mechanism of LncRNA LUCAT1 Regulating HSPB8 Expression via miR-337-3p in Modulating Neurological Damage After Cerebral Infarction - Neurochemical Research
This study aims to investigate the role of the lncRNA LUCAT1 in cerebral infarction-induced neurological damage. In vitro experiments employed N2a cells to establish an OGD/R model, while in vivo…
buff.ly
June 11, 2026 at 5:05 PM
Lei et al. recently published a study exploring how non-coding RNAs regulate HSPB8 expression and influence neuroprotection after cerebral infarction (stroke).
Check out full article
Check out full article
Free Genetic Testing
Patients with undiagnosed muscle weakness can now apply for free genetic testing. Eligible individuals can access testing through a sponsored program and detailed application instructions is available here:
Patients with undiagnosed muscle weakness can now apply for free genetic testing. Eligible individuals can access testing through a sponsored program and detailed application instructions is available here:
Genetic Testing | For Families | Cure MFM13
Complete guide to MFM13 genetic testing: how to get tested, understanding results, choosing labs, and what pathogenic HSPB8 variants mean for families.
buff.ly
May 8, 2026 at 5:04 PM
Free Genetic Testing
Patients with undiagnosed muscle weakness can now apply for free genetic testing. Eligible individuals can access testing through a sponsored program and detailed application instructions is available here:
Patients with undiagnosed muscle weakness can now apply for free genetic testing. Eligible individuals can access testing through a sponsored program and detailed application instructions is available here:
New blog post!
We break down our latest publication into a clear, accessible overview—and share the story behind the review.
Whether you're a patient, family member, clinician, or just curious, it's a great place to start.
📖 Read more: [https://buff.ly/VblMEkE]
We break down our latest publication into a clear, accessible overview—and share the story behind the review.
Whether you're a patient, family member, clinician, or just curious, it's a great place to start.
📖 Read more: [https://buff.ly/VblMEkE]
curemfm13.org
This blog provides a brief overview of a newly published review in BBA – Molecular Basis of Disease on myofibrillar myopathy type 13 (MFM13) caused by HSPB8 frameshift mutations. The paper brings…
buff.ly
May 4, 2026 at 5:03 PM
New blog post!
We break down our latest publication into a clear, accessible overview—and share the story behind the review.
Whether you're a patient, family member, clinician, or just curious, it's a great place to start.
📖 Read more: [https://buff.ly/VblMEkE]
We break down our latest publication into a clear, accessible overview—and share the story behind the review.
Whether you're a patient, family member, clinician, or just curious, it's a great place to start.
📖 Read more: [https://buff.ly/VblMEkE]
The first comprehensive review of MFM13 is now out - bringing together all current knowledge about this ultra-rare myopathy in one place.
Co-authored with Wenli Zhou, Veronica Marchesi, Barbara Tedesco & Angelo Poletti.
🔗 Read:
Co-authored with Wenli Zhou, Veronica Marchesi, Barbara Tedesco & Angelo Poletti.
🔗 Read:
Molecular, cellular, and clinical aspects of myofibrillar myopathy caused by HSPB8 frameshift mutations
HSPB8 belongs to the small heat shock proteins family, which comprises ten chaperones with molecular weights below 29 kDa. HSPB8 is broadly expressed …
buff.ly
April 10, 2026 at 5:00 PM
The first comprehensive review of MFM13 is now out - bringing together all current knowledge about this ultra-rare myopathy in one place.
Co-authored with Wenli Zhou, Veronica Marchesi, Barbara Tedesco & Angelo Poletti.
🔗 Read:
Co-authored with Wenli Zhou, Veronica Marchesi, Barbara Tedesco & Angelo Poletti.
🔗 Read:
It's been 2 years since Cure MFM13 (previously Cure HSPB8) was founded by Todd King!
Since then our main goal did not changes. We are working together to find a treatment and a cure using state-of-the-art technologies and advances in science.
#MFM13 #2anniversary #RareDiseases
Since then our main goal did not changes. We are working together to find a treatment and a cure using state-of-the-art technologies and advances in science.
#MFM13 #2anniversary #RareDiseases
April 2, 2026 at 5:01 PM
It's been 2 years since Cure MFM13 (previously Cure HSPB8) was founded by Todd King!
Since then our main goal did not changes. We are working together to find a treatment and a cure using state-of-the-art technologies and advances in science.
#MFM13 #2anniversary #RareDiseases
Since then our main goal did not changes. We are working together to find a treatment and a cure using state-of-the-art technologies and advances in science.
#MFM13 #2anniversary #RareDiseases
Tomorrow Cure MFM13 will be featured in @RareRevolutionM, an independent magazine giving a voice to the rare disease community.
For a disease with ~60 known patients, every bit of visibility matters. Stay tuned!
🔗 rarerevolutionmagazine.com
#CureMFM13 #MFM13 #HSPB8 #RareDisease
For a disease with ~60 known patients, every bit of visibility matters. Stay tuned!
🔗 rarerevolutionmagazine.com
#CureMFM13 #MFM13 #HSPB8 #RareDisease
March 30, 2026 at 5:03 PM
Tomorrow Cure MFM13 will be featured in @RareRevolutionM, an independent magazine giving a voice to the rare disease community.
For a disease with ~60 known patients, every bit of visibility matters. Stay tuned!
🔗 rarerevolutionmagazine.com
#CureMFM13 #MFM13 #HSPB8 #RareDisease
For a disease with ~60 known patients, every bit of visibility matters. Stay tuned!
🔗 rarerevolutionmagazine.com
#CureMFM13 #MFM13 #HSPB8 #RareDisease
HSPB8 beyond MFM13 function!
Piccolella M., et al., published new article, entitled "FAK signaling pathways are modulated by HSPB8 and BAG3 in breast cancer"!
Check out full publication buff.ly/c6bOwtd to learn more about HSPB8 functions in breast cancer.
Piccolella M., et al., published new article, entitled "FAK signaling pathways are modulated by HSPB8 and BAG3 in breast cancer"!
Check out full publication buff.ly/c6bOwtd to learn more about HSPB8 functions in breast cancer.
FAK signaling pathways are modulated by HSPB8 and BAG3 in breast cancer - Cell Communication and Signaling
Cell Communication and Signaling - Breast cancer (BC) is a widespread and heterogeneous disease in which autophagy plays an essential role in tumor development and progression. It has been...
buff.ly
March 17, 2026 at 5:02 PM
HSPB8 beyond MFM13 function!
Piccolella M., et al., published new article, entitled "FAK signaling pathways are modulated by HSPB8 and BAG3 in breast cancer"!
Check out full publication buff.ly/c6bOwtd to learn more about HSPB8 functions in breast cancer.
Piccolella M., et al., published new article, entitled "FAK signaling pathways are modulated by HSPB8 and BAG3 in breast cancer"!
Check out full publication buff.ly/c6bOwtd to learn more about HSPB8 functions in breast cancer.
Our 2025 Annual Report is out!
MFM13 is now officially recognized as a distinct disease entity - and that's just one of the last year's milestones. A mouse model, antibodies, community support progress - it's all in there.
Read the full report at curemfm13.org
#MFM13 #HSPB8 #RareDisease
MFM13 is now officially recognized as a distinct disease entity - and that's just one of the last year's milestones. A mouse model, antibodies, community support progress - it's all in there.
Read the full report at curemfm13.org
#MFM13 #HSPB8 #RareDisease
Cure MFM13 | Fighting Ultrarare Genetic Muscle Disorder
Dedicated to curing MFM13, an ultrarare genetic disorder marked by progressive muscle weakness. Supporting patients, families, and critical research.
curemfm13.org
March 5, 2026 at 6:02 PM
Our 2025 Annual Report is out!
MFM13 is now officially recognized as a distinct disease entity - and that's just one of the last year's milestones. A mouse model, antibodies, community support progress - it's all in there.
Read the full report at curemfm13.org
#MFM13 #HSPB8 #RareDisease
MFM13 is now officially recognized as a distinct disease entity - and that's just one of the last year's milestones. A mouse model, antibodies, community support progress - it's all in there.
Read the full report at curemfm13.org
#MFM13 #HSPB8 #RareDisease
HSPB8 roles beyond MFM13!
The new publication by Jami KM., Murray DT., et al., 2026, buff.ly/Fa3GtLQ, presents protective role of HSPB8 in neurodegenerative diseases.
The new publication by Jami KM., Murray DT., et al., 2026, buff.ly/Fa3GtLQ, presents protective role of HSPB8 in neurodegenerative diseases.
March 3, 2026 at 6:02 PM
HSPB8 roles beyond MFM13!
The new publication by Jami KM., Murray DT., et al., 2026, buff.ly/Fa3GtLQ, presents protective role of HSPB8 in neurodegenerative diseases.
The new publication by Jami KM., Murray DT., et al., 2026, buff.ly/Fa3GtLQ, presents protective role of HSPB8 in neurodegenerative diseases.
For many in the rare disease community, the journey starts with a search—not a treatment. It can take 5–7 years to get a diagnosis. This #RareDiseaseDay (Feb 28), we honor that pursuit & push for faster MFM13 diagnosis, new treatments, and stronger connections. #CureMFM13 #HSPB8
February 26, 2026 at 6:03 PM
For many in the rare disease community, the journey starts with a search—not a treatment. It can take 5–7 years to get a diagnosis. This #RareDiseaseDay (Feb 28), we honor that pursuit & push for faster MFM13 diagnosis, new treatments, and stronger connections. #CureMFM13 #HSPB8
This Valentine’s Day ❤️ we’re thinking of the families & researchers driving #CureMFM13.
We’re patient-led, and 100% of donations support #HSPB8 research & our patient registry.
Help fund a treatment: buff.ly/wIOL4qO
We’re patient-led, and 100% of donations support #HSPB8 research & our patient registry.
Help fund a treatment: buff.ly/wIOL4qO
February 12, 2026 at 6:03 PM
This Valentine’s Day ❤️ we’re thinking of the families & researchers driving #CureMFM13.
We’re patient-led, and 100% of donations support #HSPB8 research & our patient registry.
Help fund a treatment: buff.ly/wIOL4qO
We’re patient-led, and 100% of donations support #HSPB8 research & our patient registry.
Help fund a treatment: buff.ly/wIOL4qO
HSPB8 regulates CTP synthase filaments to couple nucleotide metabolism and autophagy in tumors https://www.biorxiv.org/content/10.64898/2026.02.10.704981v1
February 11, 2026 at 4:30 PM
HSPB8 regulates CTP synthase filaments to couple nucleotide metabolism and autophagy in tumors https://www.biorxiv.org/content/10.64898/2026.02.10.704981v1
HSPB8 regulates CTP synthase filaments to couple nucleotide metabolism and autophagy in tumors https://www.biorxiv.org/content/10.64898/2026.02.10.704981v1
February 11, 2026 at 4:30 PM
HSPB8 regulates CTP synthase filaments to couple nucleotide metabolism and autophagy in tumors https://www.biorxiv.org/content/10.64898/2026.02.10.704981v1
We’re proud to share that Dr. Barbara Tedesco presented her work, “Unveiling novel players in HSPB8 pathology,” at the Plenary Session “Basic Science and the Many Faces of CMT” during the 2nd European CMT Specialists Conference in Antwerp (Oct 2025).
February 5, 2026 at 6:06 PM
We’re proud to share that Dr. Barbara Tedesco presented her work, “Unveiling novel players in HSPB8 pathology,” at the Plenary Session “Basic Science and the Many Faces of CMT” during the 2nd European CMT Specialists Conference in Antwerp (Oct 2025).
Have you been wondering how exercise impacts HSPB8 levels and overall #autophagy processes in #MFM13?
There are hardly any answers to this question, but we have reviewed research available so far. Check out our website to find the most important takeaways!
buff.ly/9FOrnNa
#Exercise #HSPB8
There are hardly any answers to this question, but we have reviewed research available so far. Check out our website to find the most important takeaways!
buff.ly/9FOrnNa
#Exercise #HSPB8
Practical Information | For Families | Cure HSPB8
Personal journeys of living with MFM13. Hear from patients and families about diagnosis, daily challenges, and hope for treatment and research.
buff.ly
January 30, 2026 at 6:03 PM
Have you been wondering how exercise impacts HSPB8 levels and overall #autophagy processes in #MFM13?
There are hardly any answers to this question, but we have reviewed research available so far. Check out our website to find the most important takeaways!
buff.ly/9FOrnNa
#Exercise #HSPB8
There are hardly any answers to this question, but we have reviewed research available so far. Check out our website to find the most important takeaways!
buff.ly/9FOrnNa
#Exercise #HSPB8
New study by Yu et al. (Nanchang Univ., China) reveals a protective role of HSPB8 in type 2 diabetes. HSPB8 reduces oxidative stress and inflammation, improving diabetic cardiomyopathy in mice.
buff.ly/btSbWAh
buff.ly/btSbWAh
HSP22 reduces diabetic cardiomyopathy by inhibition oxidative stress and inflammation - PubMed
Heat shock protein 22 (HSP22) can reduce type 2 diabetes mellitus (T2DM) induced vascular endothelial injury by inhibition of inflammation and oxidative stress. Therefore, we explored whether HSP22…
pubmed.ncbi.nlm.nih.gov
January 27, 2026 at 6:04 PM
New study by Yu et al. (Nanchang Univ., China) reveals a protective role of HSPB8 in type 2 diabetes. HSPB8 reduces oxidative stress and inflammation, improving diabetic cardiomyopathy in mice.
buff.ly/btSbWAh
buff.ly/btSbWAh
HSPB8 is a member of the small heat shock protein (sHSP) family and is also known as HSP22, H11 kinase, or protein kinase H11.
January 22, 2026 at 6:02 PM
HSPB8 is a member of the small heat shock protein (sHSP) family and is also known as HSP22, H11 kinase, or protein kinase H11.
New Publication Alert
Tanya Stojkovic & Marc Bitoun explore the genetic overlap between neuropathies and myopathies, highlighting shared genes like HSPB8 (MFM13) and key diagnostic implications.
👉 Broader gene panels matter.
Read more:
Tanya Stojkovic & Marc Bitoun explore the genetic overlap between neuropathies and myopathies, highlighting shared genes like HSPB8 (MFM13) and key diagnostic implications.
👉 Broader gene panels matter.
Read more:
Chevauchement génétique entre neuropathies et myopathies : vers une convergence des deux entités | médecine/sciences
médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé
buff.ly
January 16, 2026 at 6:03 PM
New Publication Alert
Tanya Stojkovic & Marc Bitoun explore the genetic overlap between neuropathies and myopathies, highlighting shared genes like HSPB8 (MFM13) and key diagnostic implications.
👉 Broader gene panels matter.
Read more:
Tanya Stojkovic & Marc Bitoun explore the genetic overlap between neuropathies and myopathies, highlighting shared genes like HSPB8 (MFM13) and key diagnostic implications.
👉 Broader gene panels matter.
Read more: